key: cord-0854395-7vxvi45g
authors: Tignanelli, Christopher J.; Bramante, Carolyn T.; Dutta, Nirjhar; Tamariz, Leonardo; Usher, Michael G.; Ikramuddin, Sayeed
title: Metabolic Surgery May Protect Against Admission for Covid-19 in Persons with Non-Alcoholic Fatty Liver Disease.
date: 2021-06-29
journal: Surg Obes Relat Dis
DOI: 10.1016/j.soard.2021.05.029
sha: 84f7e0e85760e90f105de8f2e23662231dafdaac
doc_id: 854395
cord_uid: 7vxvi45g

BACKGROUND: Covid-19 disease causes significant morbidity and mortality through increase inflammation and thrombosis. Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are states of chronic inflammation and indicate advanced metabolic disease. The purpose of this observational study was to characterize the risk of hospitalization for Covid-19 in patients with NAFLD/NASH and evaluate the mitigating effect of various metabolic treatments. METHODS: Retrospective analysis of electronic medical record data of 26,896 adults from a 12-hospital Midwest healthcare system with a positive SARS-CoV-2 PCR from March 1, 2020 to Jan 26, 2021. Variable selection was guided by LASSO and multiple imputation was used to account for missing data. Multivariable logistic regression and competing risk models were used to assess odds of being hospitalized within 45 days of Covid-19 diagnosis. Analysis assessed the risk of hospitalization among patients with a prescription for metformin and statin use within the 3 months prior to the SARS-CoV-2 PCR result, history of home glucagon-like-peptide 1 receptor agonist (GLP-1 RA) use, and history of metabolic and bariatric surgery (MBS). Interactions were assessed by gender and race. RESULTS: A history of NAFLD/NASH was associated with increased odds of admission for Covid-19, (OR 1.88 95% CI 1.57-2.26, p<0.001)) and mortality (OR 1.96, 95% CI 1.45-2.67, p < 0.001). Each additional year of having NAFLD/NASH was associated with a significant increased risk of being hospitalized for Covid-19 (OR 1.24 95% CI 1.14-1.35, p<0.001). NAFLD/NASH increased risk of hospitalization in men, but not women, and increased risk of hospitalization in all non-white racial/ethnic subgroups. Medication treatments for metabolic syndrome were associated with significantly reduced risk of admission: OR 0.81 (0.67-0.99, p<0.001) for home metformin use and OR 0.71 (0.65-0.83, p<0.001) for home statin use. MBS was associated with a significant decreased risk of admission: OR 0.48 (0.33-0.69, p<0.001). CONCLUSIONS: NAFLD/NASH is a significant risk factor for hospitalization for Covid-19, and appears to account for risk attributed to obesity. Other significant risks include factors associated with socioeconomic status and other comorbidities, such as history of venous thromboembolism. Treatments for metabolic disease mitigated risks from NAFLD/NASH. More research is needed to confirm risk associated with visceral adiposity, and patients should be screened for and informed of treatments for metabolic syndrome.

hospitalization in all non-white racial/ethnic subgroups. Medication treatments for metabolic syndrome were associated with significantly reduced risk of admission: OR 0.81 (0.67-0.99, 25 p<0.001) for home metformin use and OR 0.71 (0.65-0.83, p<0.001) for home statin use. MBS was associated with a significant decreased risk of admission: OR 0.48 (0.33-0.69, p<0.001).

Conclusions: NAFLD/NASH is a significant risk factor for hospitalization for Covid-19, and appears to account for risk attributed to obesity. Other significant risks include factors associated 30 with socioeconomic status and other comorbidities, such as history of venous thromboembolism.

Treatments for metabolic disease mitigated risks from NAFLD/NASH. More research is needed to confirm risk associated with visceral adiposity, and patients should be screened for and informed of treatments for metabolic syndrome. Hospitalizations for Covid-19 disease continue to disrupt thousands of lives. 1 Obesity and 50 metabolic disease appear to be the most significant modifiable risk factors for poor outcomes from Covid-19. 2, 3 Hepatic steatosis (non-alcoholic fatty liver disease, NAFLD, and non-alcohol steatohepatitis [NASH] ) is evidence of visceral adiposity, advanced metabolic disease, and overt inflammation. 4 Given Covid-19's pathophysiology through inflammation, NAFLD/NASH may put patients at even higher risk of poor outcomes from Covid-19. 5 Few papers have fully 55 assessed risk for poor outcomes from Covid-19 associated with NAFLD/NASH, and factors that might reduce that risk.

We conducted a retrospective analysis of individuals with SARS-CoV-2 infection and their likelihood of being admitted for Covid-19 with the following objectives: Our primary objective 60 was to quantify the risk for hospitalization for Covid-19 based on a history of NAFLD/NASH. Our secondary objective was to assess whether treatments for metabolic disease modified risk from Covid-19 associated with NAFLD/NASH. 6, 7 Third, we were interested in whether NAFLD/NASH was associated with severe Covid-19 (intubation, mortality). Lastly, because visceral adiposity accumulates at a lower body mass index (BMI) level in men 8 and is more 65 prevalent among certain ethnic groups, [9] [10] [11] we assessed interactions between gender and race/ethnicity and NAFLD/NASH as drivers of Covid-19 outcomes.

J o u r n a l P r e -p r o o f Design and data source 70

Retrospective cohort analysis of electronic medical record data pooled across 12 hospitals and 56 primary care clinics in the Midwest, the Acute and Chronic Datamart for COVID (ACDC). This COVID-19 datamart includes clinical and administrative data for individuals with a positive SARS-CoV-2 PCRtest. Data were pooled across different EHRs to account for patient transfers and all encounters between systems for each patient, facilitated by generating a Master Patient 75

Index serving as a unique patient identifier. In cases where a patient was seen in two different EHR systems, the most recent EHR comorbidity and outpatient medication records were used.

All patients who opted out of research were excluded from analysis. 

Persons with NAFLD/NASH were defined as those with ICD codes for NAFLD or NASH or a BMI >= 30kg/m 2 and an elevated alanine aminotransferase (ALT) on 3 separate dates. 12 This lab and BMI-based definition was used in addition to ICD coding because NASH and NAFLD are significantly underdiagnosed in the her, 13, 14 and because elevated ALT is more specific for 90 NAFLD/NASH than elevated AST. 15 J o u r n a l P r e -p r o o f 

There was an overall low rate of data missingness. 1913 patients (7.1%) were missing comorbidity data, 4055 (15.1%) were missing race data, 58 (0.2%) were missing age data, and 2 (0.01%) were missing sex data. There was no missingness in other variables. To account for missing data, we used the multiple imputation (mi) suite of commands, with five imputations for each missing value. 16 125

Analyses:

Multivariable logistic regression was used to assess odds of being hospitalized within 45 days of a positive Covid-19 PCR test. To account for the competing risk that patients may die prior to hospitalization, a competing risk model was also utilizing. The dependent variable in the 130 competing risk was the time to hospitalization censored at 45 days. Both models were adjusted for variables selected using LASSO. Interactions were assessed by gender and race.

A subgroup analysis of patients with only NAFLD or NASH was also conducted to evaluate the independent association of metformin use, GLP-1RA use, and previous bariatric surgery on hospitalization. In order to account for variables that can worsen NAFLD/NASH, a 135 sensitivity analysis was also done excluding patients with a history of alcohol use disorder, home amiodarone or methotrexate use. 17 Table 2 .

To evaluate gender-specific interaction, NAFLD/NASH in men was associated with increased odds of admission: 1.4 (1.02-1.96, p=0.04), but not in women: OR 0.71 (0.51-0.98, p=0.04), 175

suggesting gender specific derangements related to NAFLD/NASH may be driving increased risk of worse outcomes in Covid-19 (Table 3) .

Persons who had undergone bariatric surgery, n=343, had significantly decreased odds of admission for Covid-19, OR 0.46 (0.33-0.68, p<0.001) (Supplemental Table 1 and Figure 2) . 

Discussion This is an in-depth assessment of NAFLD/NASH as a risk factor for admission for Covid-19 in a large database in the US, as well as possible treatments for mitigating this risk. We found that 210 NAFLD/NASH was a significant risk factor for admission. This may indicate the significant role of visceral adiposity in the pathophysiology of Covid-19, which appears to amplify the chronic state of inflammation and hypercoagulability created by NAFLD/NASH.

specific sex-specific differences in the accumulation of visceral adiposity. 18 Assessing an interaction with race was done because of significant differences in outcomes in Covid-19 by race and ethnicity. 19 NAFLD/NASH increased risk of hospitalization in all groups, but controlling for NAFLD/NASH did not eliminate differences in risk between racial/ethnic groups.

Of note, persons who had self-identified as Black who had NAFLD/NASH had the biggest 220 increased odds of hospitalization. This may be due to lower amounts of visceral adiposity previously reported in Black individuals. 20 Promisingly, we found that treatments for metabolic syndrome and NAFLD/NASH greatly mitigated risks from Covid-19. Bariatric surgery is one of the most effective treatments for 225 metabolic syndrome, and in this analysis persons who had undergone bariatric surgery had a significant decrease in odds of hospitalization.

While the protective benefits of metformin, GLP-1RA, and bariatric surgery are promising, more therapies for NAFLD/NASH are urgently needed. The mainstay of treatment for NAFLD/NASH 230 is weight loss, and while advances in obesity medicine have made achieving sustainable weight loss more possible, 19 societal forces including the current Covid-19 pandemic, continue to create an obesogenic environment as over 42% of adults in the US now have obesity. 21 Our study has several limitations: there may be unmeasured confounders and residual bias in 235 observational findings. Findings in a sample in the upper Midwest may not be generalizable.

Hepatitis B and C were not excluded as they may co-occur with NAFLD/NASH in persons with BMI>=30kg/m 2 , and the prevalence in this region is low: 0.78% of adults with hepatitis C and 0.59% with chronic hepatitis B. Further selection bias may be present in that there are likely many more individuals in this population who have NAFLD/NASH but who did not have 3 240 elevated ALT readings. 4 This selection bias would likely bias findings towards the null.

NAFLD/NASH is a state of chronic inflammation due to visceral adiposity and appears to be a significant risk factor for hospitalization for Covid-19. NAFLD/NASH may account for much of 245 the risk for poor outcomes from Covid-19 attributed to obesity. Bariatric surgery appears to mitigate elevated risk for hospitalization for Covid-19 in persons with NAFLD/NASH. More research is needed to confirm these findings. Patients with elevated BMI should be screened for NAFLD/NASH and metabolic syndrome and informed of the risks associated with visceral adiposity and Covid-19. Patients should also be informed of treatments for mitigating this risk 250 such as bariatric surgery and some medications. 10, 19 J o u r n a l P r e -p r o o f Acknowledgements: Dr. Tignanelli is PI on randomized trials for Covid-19, but not related to 260 metformin. Dr. Bramante has submitted an IND for a prospective trial for metformin. 

Transforming a Long-Term Acute Care Hospital into a COVID-19-Designated Hospital

Obesity aggravates COVID-19: a systematic review and meta-analysis

Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study

Nonalcoholic Steatohepatitis: A Review

Immunomodulation in COVID-19

US Preventive Services Task Force; 2012 Web site

Metformin and Risk of Mortality in Patients Hospitalized with Covid-19: a retrospective cohort analysis

Identification of sex-specific thresholds for accumulation of visceral adipose tissue in adults

Relationship between body fat and BMI in a US hispanic population-based cohort study: Results from HCHS/SOL

AHA/ACC/TOS guideline for the 330 management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society

Abdominal Obesity Measurement Guidelines for Different Ethnic Groups

The International Diabetes Federation's definition of the metabolic syndrome uses ethnic-specific criteria to define abdominal obesity

Non-alcoholic fatty liver disease -histological 340 scoring systems: a large cohort single-center, evaluation study

Current Modalities of Fibrosis Assessment in Nonalcoholic Fatty Liver Disease

Application of Machine Learning Methods 345 to Predict Non-Alcoholic Steatohepatitis (NASH) in Non-Alcoholic Fatty Liver (NAFL) Patients

Association between the alanine aminotransferase/aspartate aminotransferase ratio and new-onset non-alcoholic fatty liver disease in a nonobese Chinese population: a population-based longitudinal study. 350 Lipids in Health and Disease

Nationwide cohort study of independent risk factors for acute respiratory distress syndrome after trauma

Effect of chronic alcohol 355 consumption on the development and progression of non-alcoholic fatty liver disease (NAFLD)

Visceral adipose tissue measured by DXA correlates with measurement by CT and is associated with cardiometabolic risk factors in children

Geographic Availabiliy of Physicians Certified by the American Board of Obesity Medicine Relative ot Obesity Prevalence

Visceral fat, waist circumference, and BMI: impact of race/ethnicity. Obesity (Silver Spring, Md)

Prevalence of Obesity and Severe Obesity Among Adults: United States

J o u r n a l P r e -p r o o f Supplemental